Glaukos (GKOS) executive Navratil sold 44,436 shares for $10.6M at an average $238.97
Glaukos CDO Navratil exercised 12,969 options and sold 44,436 shares at ~$238.97, about $10.6M, leaving 37,328 direct shares.
Insider transactions reported
Tomas Navratil (Chief Development Officer at Glaukos Corporation, GKOS) reported that they sold 44,436 shares for $10.6M at an average $238.97, and acquired 12,969 shares at an average $75.97 on Oct 30, 2026. After these transactions the filing shows 37,328 shares held directly.
- Reporting person
- Navratil Tomas
- Role
- CHIEF DEVELOPMENT OFFICER
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Exercise or conversion of a derivative (M) | Common Stock1, 2 | +12,969 | avg $75.97 | $985K | 81,764 direct |
| Oct 30, 2026 | Open-market sale (S) | Common Stock2, 3, 4, ... | -44,436 | avg $238.97 | $10.6M | 37,328 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 12,969 Common Stock7 | -12,969 | - | - | 0 direct |
Holdings before and after
- Common Stock: 68,795 to 37,328 direct
- Stock Option (Right to Buy): 4,181 to 0 direct
Footnotes from the filing
- 1. Includes 37,328 restricted stock units that have not yet vested or been delivered to the Reporting Person. Additionally, the amount reported has been adjusted by 259 shares to correct a clerical error.
- 2. Includes 37,328 restricted stock units that have not yet vested or been delivered to the Reporting Person.
- 3. This transaction was executed in multiple trades at prices ranging from $237.09 to $238.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. This transaction was executed in multiple trades at prices ranging from $238.11 to $239.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was
- 7. These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Navratil report in this GKOS Form 4?
Tomas Navratil (Chief Development Officer at Glaukos Corporation, GKOS) reported that they sold 44,436 shares for $10.6M at an average $238.97, and acquired 12,969 shares at an average $75.97 on Oct 30, 2026. After these transactions the filing shows 37,328 shares held directly.
How many GKOS shares does Navratil hold after this filing?
The filing shows 37,328 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this GKOS insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for GKOS
Across the 27 sessions after earlier GKOS headlines, the stock closed higher 18 times and lower 9 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GKOS | SPY |
|---|---|---|---|
| Nov 3, 2026 | Glaukos Announces Participation in Upcoming Investor Conferences | -2.3% | +0.3% |
| Oct 29, 2026 | Glaukos Announces Third Quarter 2026 Financial Results | +33.6% | -0.4% |
| Oct 9, 2026 | Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery | +2.7% | +0.6% |
| Oct 8, 2026 | Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseasesand 1 other headline that session | -6.3% | -0.4% |
| Oct 7, 2026 | Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 | +6.6% | -0.2% |
| Sep 23, 2026 | Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus | -4.0% | -0.7% |
Earlier insider filings at GKOS
- Nov 4, 2026CHIEF DEVELOPMENT OFFICER Navratil Tomas covered exercise/tax liability with 755 shares, decreasing direct ownership by 1% to 68,536 units (SEC Form 4) (withholding tax)
- Oct 7, 2026CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $251,120 worth of shares (1,527 units at $164.45) as part of a pre-agreed trading plan (SEC Form 4)
- Sep 28, 2026CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $249,158 worth of shares (1,615 units at $154.28) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 70,818 units (SEC Form 4)
- Sep 18, 2026CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $243,204 worth of shares (1,457 units at $166.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 72,433 units (SEC Form 4)
- Sep 1, 2026CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $2,483,104 worth of shares (13,744 units at $180.67), decreasing direct ownership by 16% to 73,890 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2015
Follow GKOS and get a push notification the moment its next story breaks.